HC Wainwright Issues Pessimistic Forecast for AARD Earnings

Aardvark Therapeutics, Inc. (NASDAQ:AARD) – Investment analysts at HC Wainwright lowered their FY2025 earnings estimates for shares of Aardvark Therapeutics in a note issued to investors on Thursday, December 11th. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings per share of ($2.93) for the year, down from their previous estimate of ($2.83). HC Wainwright currently has a “Buy” rating and a $40.00 target price on the stock. HC Wainwright also issued estimates for Aardvark Therapeutics’ Q4 2025 earnings at ($0.80) EPS, Q1 2026 earnings at ($0.87) EPS, Q2 2026 earnings at ($0.95) EPS, Q3 2026 earnings at ($0.88) EPS and FY2026 earnings at ($3.65) EPS.

Aardvark Therapeutics (NASDAQ:AARD) last posted its quarterly earnings results on Thursday, November 13th. The company reported ($0.75) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.82) by $0.07.

A number of other research firms also recently commented on AARD. Jones Trading started coverage on shares of Aardvark Therapeutics in a report on Wednesday, October 1st. They set a “buy” rating and a $33.00 price objective on the stock. William Blair began coverage on Aardvark Therapeutics in a report on Friday. They issued an “outperform” rating on the stock. Royal Bank Of Canada dropped their price target on Aardvark Therapeutics from $19.00 to $18.00 and set an “outperform” rating for the company in a research report on Friday, November 14th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Aardvark Therapeutics in a research note on Monday, December 8th. Finally, Raymond James Financial initiated coverage on shares of Aardvark Therapeutics in a research note on Tuesday, December 2nd. They issued a “strong-buy” rating and a $47.00 price objective on the stock. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Aardvark Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $32.44.

Aardvark Therapeutics Stock Up 0.3%

NASDAQ:AARD opened at $14.47 on Monday. The firm’s fifty day simple moving average is $11.88 and its 200-day simple moving average is $11.75. The stock has a market cap of $315.01 million and a PE ratio of -6.83. Aardvark Therapeutics has a fifty-two week low of $4.88 and a fifty-two week high of $19.58.

Insider Activity

In related news, CEO Tien-Li Lee purchased 7,000 shares of the company’s stock in a transaction that occurred on Thursday, December 11th. The stock was purchased at an average price of $14.48 per share, with a total value of $101,360.00. Following the completion of the transaction, the chief executive officer owned 1,551,613 shares of the company’s stock, valued at approximately $22,467,356.24. This trade represents a 0.45% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Nelson Sun purchased 3,000 shares of the business’s stock in a transaction on Thursday, December 11th. The shares were bought at an average cost of $14.40 per share, for a total transaction of $43,200.00. Following the purchase, the chief financial officer owned 108,484 shares of the company’s stock, valued at $1,562,169.60. This trade represents a 2.84% increase in their ownership of the stock. The SEC filing for this purchase provides additional information.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the company. Goldman Sachs Group Inc. acquired a new stake in Aardvark Therapeutics during the first quarter worth about $153,000. Adage Capital Partners GP L.L.C. acquired a new position in shares of Aardvark Therapeutics during the 1st quarter valued at $1,878,000. Cormorant Asset Management LP purchased a new stake in shares of Aardvark Therapeutics in the first quarter worth about $6,009,000. Walleye Capital LLC purchased a new position in Aardvark Therapeutics in the 1st quarter worth approximately $88,000. Finally, Braidwell LP acquired a new stake in Aardvark Therapeutics during the 1st quarter valued at $3,755,000.

About Aardvark Therapeutics

Aardvark Therapeutics, Inc operates as a biotechnology company. It engages in the development of a novel small molecule therapeutics for obesity and metabolic diseases. The company was founded by Tien Lee in 2017 and is headquartered in San Diego, CA.